Avalo Therapeutics's total assets for Q4 2024 were $150.73M, an increase of 53.10% from the previous quarter. AVTX total liabilities were $17.70M for the fiscal quarter, a -77.13% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.